Journal article
Effectiveness of anti-obesity medications approved for long-term use in a multidisciplinary weight management program: a multi-center clinical experience
International journal of obesity (2005), Vol.46(3), pp.555-563
03/2022
DOI: 10.1038/s41366-021-01019-6
PMCID: PMC8881310
PMID: 34811486
Abstract
Randomized clinical trials have proven the efficacy and safety of Food and Drug Administration (FDA) approved anti-obesity medications (AOMs) for long-term use. It is unclear whether these outcomes can be replicated in real-world clinical practice where clinical complexities arise. The aim of this study was to evaluate the effectiveness and side effects of these medications in real-world multidisciplinary clinical practice settings.
We reviewed the electronic medical records (EMR) of patients with obesity who were prescribed an FDA-approved AOM for long-term use in academic and community multidisciplinary weight loss programs between January 2016 and January 2020.
We assessed percentage total body weight loss (%TBWL), metabolic outcomes, and side effect profile up to 24 months after AOM initiation.
The full cohort consisted of 304 patients (76% women, 95.2% White, median age of 50 years old [IQR, 39-58]). The median follow-up time was 9.1 months [IQR, 4.2-14.1] with a median number of 3 visits [IQR, 2-4]. The most prescribed medication was phentermine/topiramate extended-release (ER) (51%), followed by liraglutide (26.3%), bupropion/naltrexone sustained-release (SR) (16.5%), and lorcaserin (6.2%). %TBWL was 5.0%, 6.8%, 9.3%, 10.3%, and 10.5% at 3, 6, 12, 18, and 24 months. 60.2% of the entire cohort achieved at least 5% TBWL. Overall, phentermine/topiramate-ER had the most robust weight loss response during follow-up, with the highest %TBWL at 12 months of 12.0%. Adverse events were reported in 22.4% of patients. Only 9% of patients discontinued the medication due to side effects.
AOMs resulted in significant long-term weight loss, that was comparable to outcomes previously reported in clinical trials.
Details
- Title: Subtitle
- Effectiveness of anti-obesity medications approved for long-term use in a multidisciplinary weight management program: a multi-center clinical experience
- Creators
- Gerardo Calderon - Mayo Clinic in ArizonaDaniel Gonzalez-Izundegui - Mayo Clinic in ArizonaKuangda L Shan - Roy J. and Lucille A. Carver College of MedicineOscar A Garcia-Valencia - Mayo Clinic in ArizonaLizeth Cifuentes - Mayo Clinic in ArizonaAlejandro Campos - Mayo Clinic in ArizonaMaria L Collazo-Clavell - Mayo Clinic in ArizonaMeera Shah - Mayo Clinic in ArizonaDaniel L Hurley - Mayo Clinic in ArizonaHaitham S Abu Lebdeh - Mayo Clinic in ArizonaMayank Sharma - Mayo Clinic in ArizonaKristine Schmitz - Mayo Clinic in ArizonaMatthew M Clark - Division of Endocrinology, Diabetes, Metabolism & Nutrition, Mayo Clinic, Rochester, MN, USA.Karen Grothe - Division of Endocrinology, Diabetes, Metabolism & Nutrition, Mayo Clinic, Rochester, MN, USA.Manpreet S Mundi - Mayo Clinic in ArizonaMichael Camilleri - Mayo Clinic in ArizonaBarham K Abu Dayyeh - Mayo Clinic in ArizonaMaria D Hurtado Andrade - Mayo Clinic Health SystemMohamad A Mokadem - Roy J. and Lucille A. Carver College of MedicineAndres Acosta - Mayo Clinic in Arizona
- Resource Type
- Journal article
- Publication Details
- International journal of obesity (2005), Vol.46(3), pp.555-563
- DOI
- 10.1038/s41366-021-01019-6
- PMID
- 34811486
- PMCID
- PMC8881310
- NLM abbreviation
- Int J Obes (Lond)
- ISSN
- 0307-0565
- eISSN
- 1476-5497
- Grant note
- K23 DK114460 / NIDDK NIH HHS
- Language
- English
- Date published
- 03/2022
- Academic Unit
- Gastroenterology and Hepatology; Internal Medicine
- Record Identifier
- 9984359889902771
Metrics
29 Record Views